MOSCOW, April 8 – RIA Novosti. EpiVacCorona is suitable for re-vaccination against coronavirus, Rinat Maksyutov, Director General of the State Research Center for Virology and Biotechnology Vector of Rospotrebnadzor, said in an interview with RIA Novosti.
“The EpiVacCorona vaccine is fully suitable for revaccination,” he said.
EpiVacCorona is the second drug registered in Russia for the prevention of COVID-19.
The vaccine does not contain a live virus. It builds immunity through the use of artificially synthesized peptides. The drug will cost up to 4210 rubles.
Rospotrebnadzor noted that not all tests will be able to detect antibodies to coronavirus after using EpiVacCorona, therefore, special testing systems will be supplied with this drug.
Also registered in Russia are “Sputnik V”, created by the Gamaleya Center, and “KoviVak” from the Chumakov Center of the Russian Academy of Sciences. All three drugs are on the list of essential drugs.